Vaxart reports Q3 revenue $72.4M, net loss $8.1M; signs Dynavax COVID-19 pill license deal worth up to $700M

Vaxart, Inc.

Revenue $72.4M (vs $4.9M Q3 2024) from BARDA contract; net loss $8.1M ($0.04 EPS) vs $14.1M loss.
Exclusive license with Dynavax: $25M upfront + $5M equity; up to $700M in milestones and royalties.
Phase 2b COVID-19 trial enrollment completed (~5,400); topline data expected late 2026, sentinel cohort Q1 2026.
Cash, equivalents, investments $28.8M; with Dynavax payment runway extended to Q2 2027.
Phase 1 norovirus oral vaccine data shows robust fecal IgA; partnership discussions ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.